Sofinnova News
Sofinnova Industrial Biotech
2024 Impact Report: Delivering impact
Read all about how the entrepreneurs we support are working to make industry and agriculture more sustainable
Related Strategy
Industrial BiotechClick here to download full report
The vision for the Industrial Biotech strategy emerged about 15 years ago with the conviction that there was a huge, untapped opportunity to apply our life sciences investment knowledge to assist sustainability-focused entrepreneurs turning science into innovation.
Our mission is to use biotechnology to make the world more sustainable while generating outsized returns. We focus on the agriculture, food, chemicals, and materials verticals, as they are secular markets in which biotech can achieve significant impact. This practice has shown that targeting environmental impact not only benefits the environment, but also yields strong financial returns.
As pioneers in this space, we have accumulated a unique perspective in scaling biotech startups manufacturing industrial goods. Since our inception, we have tried to improve the world through innovative, impact-focused start-ups.
The world’s need for environmental action is even greater now than when we started. Governments and industries are mandating aggressive climate regulations, consumers are demanding replacements for their everyday products, and global brands are making strong sustainability commitments. Our team is convinced that the most successful companies of the next decades will be those using innovative technologies to tackle climate change and environmental challenges.
We lead investments in early-stage rounds (Seed, Series A and B), providing visionary entrepreneurs with the capital to drive real change towards a new sustainable approach to producing and consuming goods globally. However, our commitment goes far beyond just money. As advisors, ecosystem connectors, committed board members, and partners, we provide the expertise and experience needed to scale innovative solutions and build the future.
Click on the link at the top of this page to delve into the latest edition of the industrial biotech impact report.
Related News
Sofinnova Partners raises €1.2 billion to fuel the next wave of life sciences innovation
Amid the buzz at JP Morgan conference, Sofinnova Partners' Antoine Papiernik is optimistic
Bon Vivant achieves self-affirmed GRAS status, notifying the FDA of its recombinant whey protein enabling commercialization in the U.S.
The KnOWLedge Project
Handbook for impact accountability in VC developed by coalition of impact-driven funds